Aquarius Population Health

Could we optimise testing for gonorrhoea to avoid the use of last-line antibiotics?

Ceftriaxone is the first-line treatment for gonorrhoea but there are few alternative treatments available should ceftriaxone resistance become widespread. Aquarius created a model to explore how point-of-care testing could be used to diagnose gonorrhoea and at the same time test for antibiotic susceptibility, which could allow the use of previously abandoned antibiotics for many patients, Read More >

How can economic models inform decision-making about screening programmes?

Dr Elisabeth Adams, Managing Director and Founder of Aquarius Population Health, spoke at a continuing medical education webinar for health professionals hosted on September 23,2020 by the Consortium for Infectious Disease Control (CIDC).   With increasing demands on time and resources, decision-makers in healthcare need information about how to create a safe, effective and cost-effective Read More >

How much would community-based screening for chlamydia and gonorrhoea cost?

We collaborated with St George’s, University of London, on a NIHR-funded study ‘Test n Treat’ (TnT). This study assessed the cost of providing same-day chlamydia and gonorrhoea testing and treatment service at higher education colleges. The paper presenting this work was published in BMC Health Services Research and is now available online. Read More >